Next Article in Journal
Non-Coding RNAs in Muscle Dystrophies
Next Article in Special Issue
A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin
Previous Article in Journal
Advanced Knowledge of Three Important Classes of Grape Phenolics: Anthocyanins, Stilbenes and Flavonols
Previous Article in Special Issue
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Int. J. Mol. Sci. 2013, 14(10), 19670-19680; doi:10.3390/ijms141019670

BTG1 Expression Correlates with the Pathogenesis and Progression of Ovarian Carcinomas

1 Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China 2 Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University, Shenyang 110001, China 3 Clinical Cancer Institute, Kanagawa Cancer Center, Yokohama 241-0815, Japan
* Author to whom correspondence should be addressed.
Received: 13 May 2013 / Revised: 5 September 2013 / Accepted: 6 September 2013 / Published: 27 September 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [1265 KB, uploaded 19 June 2014]   |  


BTG (B-cell translocation gene) can inhibit cell proliferation, metastasis, and angiogenesis and regulate cell cycle progression and differentiation in a variety of cell types. We aimed to clarify the role of BTG1 in ovarian carcinogenesis and progression. A BTG1-expressing plasmid was transfected into ovarian carcinoma cells and their phenotypes and related proteins were examined. BTG1 mRNA expression was detected in ovarian normal tissue (n = 17), ovarian benign tumors (n = 12), and ovarian carcinoma (n = 64) using real-time RT-PCR. Ectopic BTG1 expression resulted in lower growth rate, high cisplatin sensitivity, G1 arrest, apoptosis, and decreased migration and invasion. Phosphoinositide 3-kinase, protein kinase B, Bcl-xL, survivin, vascular endothelial growth factor, and matrix metalloproteinase-2 mRNA and protein expression was reduced in transfectants as compared to control cells. There was higher expression of BTG1 mRNA in normal tissue than in carcinoma tissue (p = 0.001) and in benign tumors than in carcinoma tissue (p = 0.027). BTG1 mRNA expression in International Federation of Gynecology and Obstetrics (FIGO) stage I/II ovarian carcinomas was higher than that in FIGO stage III/IV ovarian carcinomas (p = 0.038). Altered BTG1 expression might play a role in the pathogenesis and progression of ovarian carcinoma by modulating proliferation, migration, invasion, the cell cycle, and apoptosis.
Keywords: ovarian carcinoma; BTG1; phenotypes; tumorigenesis; progression ovarian carcinoma; BTG1; phenotypes; tumorigenesis; progression
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material


Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Zhao, Y.; Gou, W.-F.; Chen, S.; Takano, Y.; Xiu, Y.-L.; Zheng, H.-C. BTG1 Expression Correlates with the Pathogenesis and Progression of Ovarian Carcinomas. Int. J. Mol. Sci. 2013, 14, 19670-19680.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert